Key facts
- This page summarizes Stephen Feider's Form 3 filing for Beta Bionics, Inc. (BBNX).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 29 Jan 2025, 21:40.
Stephen Feider - 29 Jan 2025 Form 3 Insider Report for Beta Bionics, Inc. (BBNX)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- BBNX
- Reported as of
- 29 Jan 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 29 Jan 2025, 21:40:12 UTC
- Next SEC filing
- 03 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stephen Feider
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Stephen Feider filed Form 3 for Beta Bionics, Inc. (BBNX) on 29 Jan 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BBNX
holding
Derivative
Employee Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Jan 2025
- Ownership
- Direct
- Underlying class
- Class B Common Stock
- Underlying amount
- 166,542
- Exercise price
- $7.51
- Footnotes
- F1, F2
BBNX
holding
Derivative
Employee Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Jan 2025
- Ownership
- Direct
- Underlying class
- Class B Common Stock
- Underlying amount
- 109,695
- Exercise price
- $5.10
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
One-fourth of the shares subject to this option shall vest one year after August 1, 2022, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof.
Footnote F2
In accordance with the Issuer's Amended and Restated Certificate of Incorporation, the Issuer's outstanding shares of Class B Common Stock will convert into an equal number of shares of Common Stock immediately prior to the closing of the initial public offering.
Footnote F3
The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.